Migraine costs you for decades; your tracking app shouldn't.

The log you lose the month you feel better

You cancel the tracking app during a good stretch. The attacks had thinned out, the monthly charge felt like paying for a gym you'd stopped visiting, so you tapped cancel.

Three months later the mornings start again. The residual photophobia. The neck stiffness that outlasts the head pain by a full day. So you resubscribe. And every log you built, the medication-response notes, the postdrome timelines, the triggers you had finally pinned down after two years of guessing, sits behind the wall you stopped feeding.

That is the migraine subscription in one scene. You pay most when you are sickest, you get punished for the months you improve, and the meter never actually stops.

The Decade Test

Here is a rule for every cost that attaches itself to migraine: run it over a decade before you decide it's small.

Migraine is measured in decades, not billing cycles. A tracking cost that looks trivial at five dollars a month is not being sold to you for a month. It is being sold to you for the length of the disease, and the disease does not offer a loyalty discount. Anything you pay every month, you pay roughly 360 times over thirty years, and you pay it hardest in the years the condition is worst.

Most migraine budgeting fails because it stops at the copay in front of you. The Decade Test forces the honest number: what does this line item cost across the actual span you'll live with this?

Why "it's only five bucks a month" is the wrong comparison

Subscription pricing survives on one comparison: the app versus a coffee. Framed that way, five dollars is nothing, and you feel unreasonable for hesitating.

Two things break that comparison. First, chronic migraine is not a subscription you churn out of. You don't finish it. The good quarters end and the app is still charging, so the coffee-a-month framing quietly becomes a thousand-dollar framing without anyone saying the number out loud. Second, what you're renting is your own history. The value in a tracker is the years of continuous data, the medication that worked in 2027 and stopped working in 2029, the postdrome patterns you can hand a neurologist in ninety seconds. A subscription holds that hostage. Stop paying and your own record goes dark.

The right comparison isn't a coffee. It's every other recurring bill your condition already generates.

The arithmetic nobody adds up in one place

Put the recurring costs of a life with chronic migraine side by side and the tracking app stops looking like the cheap one and starts looking like the sneaky one, because it's the smallest number that behaves exactly like the biggest ones: it recurs, and it compounds.

The drug bill is the headline. CGRP monoclonal antibodies (Aimovig, Ajovy, Emgality, Vyepti, Qulipta) carry a list price around $700 a month, and insurance prior authorization for that class requires documented attack frequency, making rigorous tracking a direct financial necessity for patients, not just a convenience. Coverage swings on step-therapy and prior-auth rules that change year to year. Then the appointments: neurologist and headache-specialist visits at a cadence chronic migraine dictates, each with its own out-of-pocket cost. Then the largest and least-counted bucket, lost work and productivity, which migraine-burden research puts at $11,294 per migraine patient annually versus $8,945 for matched controls, a $2,350 incremental difference. ([source](https://headachejournal.onlinelibrary.wiley.com/doi/abs/10.1111/head.13275))

Against those, the app subscription is small. It is also the only one on the list you can end permanently with a single decision.

One ledger, thirty years

Picture the arithmetic for someone diagnosed at 28. Episodic at first, chronic by 35. She tries her first tracking app in a flare, cancels it two years later during a stretch of remission on a new preventive, loses the history, then rebuilds it from scratch when the attacks return at 40. She does that cycle three times across her thirties and forties, paying the setup cost in effort every time and the subscription in dollars the whole way.

The drug spend over those decades runs into five figures even with decent coverage. The appointments add thousands. The lost income, if her worst years cost her promotions or hours, dwarfs both. And threaded through all of it is a recurring app charge that, taken over the full span, quietly clears a thousand dollars while she loses her own timeline twice.

Every expensive line on that ledger is fixed by medicine or insurance or nothing. The one line she could have fixed with a single purchase, she instead paid for 360 times.

Price the tool like a tool

If migraine is a decades-long cost, the mismatch is obvious the moment you say it plainly: a chronic condition tracked on a recurring bill is a structural conflict of interest. The subscription vendor's incentive is retention. Yours is a good enough record that you eventually need the app less, not more.

Recurring pricing rewards the vendor for your condition persisting. One-time pricing doesn't care whether you open the app daily for a decade or twice a month for twenty years. The relationship stops depending on your worst weeks.

That's the whole argument for pricing a tracker like a tool you own instead of a service you rent. Not because a thousand dollars over thirty years will break anyone next to a CGRP bill. Because it is the one line on the entire ledger where the incentive can point at the patient instead of away.

The line that doesn't compound

Postdrome costs $14.99 once. That is the number, stated up front, with nothing recurring behind it.

Against a lifetime migraine ledger that runs well into five or six figures, that price is a rounding error, and that is exactly the point. The tracking layer should be the one cost on the whole list that ends. Your continuous symptom timeline, the postdrome after-phase most apps stop recording, the medication-response history, all of it lives on your device and leaves with you if you ever go. There is no wall to fall behind in the month you finally feel better.

We can't touch your drug bill or your insurer's appeal process. We can make sure the thing you use to document all of it isn't quietly compounding against you for thirty years.

What we're watching

The variable that actually moves your lifetime number isn't the app. It's coverage. We're tracking insurer step-therapy and prior-auth changes on the CGRP class, because a formulary decision can shift years of out-of-pocket spend in a direction no tracker can offset. When one of those changes lands, we'll translate it into plain English and what it means for your ledger.